Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ACADEMIA
ACADEMIA
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
- 80% of Medical Institutions Say Reimbursement Fees “Essential” to Introduce Formularies: Study
February 8, 2023
- Over Half of Pregnant Women Shun COVID Jab for Side Effect Fears: Survey
December 6, 2022
- Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
- Building Delivery Scheme for Disease-Modifying Drugs for Alzheimer’s Is Critical: Academic Societies
November 30, 2022
- Obesity Society to Highlight Proper Use of Semaglutide If Label Expanded
November 29, 2022
- Japan Infectious Diseases Association Updates Guidelines after Xocova Approval
November 25, 2022
- Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
- Japan Pediatric Society Recommends COVID Jab for Ages 4 Years and Younger
November 4, 2022
- Researchers Launch Scientific Society for Oncolytic Virus Therapies
October 31, 2022
- Less than Half of Japan Prefectures Offer SMA Test under Newborn Screening Program: Survey
October 28, 2022
- Japan Expert Sees Lecanemab Initially Treating Only a Few Tens of Thousands of Patients with Immature Care Setup
October 12, 2022
- 3rd COVID-19 Shot for Kids Aged 5-11 Effective as Booster: Infectious Diseases Association
October 5, 2022
- Antimicrobial Use in 2021 Down 31.5% from 2013: Expert
October 5, 2022
- Ivermectin Fails in Investigator-Led COVID Trial Too
October 3, 2022
- Emergency Approval Push for Shionogi’s COVID Pill Not Profit-Driven: Academic Societies
September 9, 2022
- University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
- Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
- Japanese Society of Formulary to Support Regional Initiatives: President
August 18, 2022
- Japan Pediatric Society Recommends COVID Jab for Ages 5-17
August 12, 2022
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…